Vaxcyte, Inc.
PCVX
Updated: 23/09/2026, 09:29:40
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
No summaries found.
- Share price
- $59.02
- Market cap
- $8.52B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Grant E. Pickering
- Employees
- 507
- IPO date
- 12/06/2020
- Beta
- 1.22
- Last dividend
- $0.00
- Day range
- $58.70 – $59.90
- 52-week range
- $31.89 – $65.00
- 1-day performance
- 0.17%
- 1-year performance
- 85.07%
- Current drawdown (1Y)
- -9.20%
- CIK
- 0001649094
- CUSIP
- 92243G108
- ISIN
- US92243G1085
- Created
- 07/12/2025, 05:41:57
- Last update
- 23/09/2026, 09:29:40
Track Vaxcyte, Inc. with an AI analyst
See which prediction-market events move PCVX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
GlobeNewsWire • STOCK • 02/06/2026, 18:05:00
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 21:10:45
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Seeking Alpha • STOCK • 02/05/2026, 00:59:00
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
GlobeNewsWire • STOCK • 23/03/2026, 09:30:00
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
GlobeNewsWire • STOCK • 18/03/2026, 20:34:00
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 25/02/2026, 00:27:52
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewsWire • STOCK • 02/02/2026, 17:05:00